Emerging Therapeutic Strategies for Drug-induced Pulmonary Injury: A Mini Review
Article Sidebar
Main Article Content
Abstract
Drug-induced pulmonary injury (DIPI) represents a significant, though often under-recognized, complication of pharmacotherapy. With the increasing global use of chemotherapeutic agents, immunomodulators, and novel biologics, the reported incidence of DIPI is rising, thereby posing significant diagnostic and management challenges. This mini-review outlines the mechanisms, clinical manifestations, and current treatment approaches for DIPI, while highlighting recent advances in biomarker discovery and targeted interventions. This review emphasizes early detection and personalized management to mitigate morbidity and mortality associated with this condition.
Article Details
Copyright (c) 2026 Liya S.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022:2022 Oct 27;60(4):2102776. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J. 2001. Available from: https://doi.org/10.1183/13993003.02776-2021
Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021 May 28;12:663986. Available from: https://doi.org/10.3389/fimmu.2021.663986
Burman S, Das A, Gupta N. Atypical radiological presentation of bleomycin-induced lung injury: Case report and review of literature. Curr Med Res Pract. 2020: 10(5):p 244-247. Available from: https://doi.org/10.4103/cmrp.cmrp_20_20
Tomos I, Roussis I, Matthaiou AM, Dimakou K. Molecular and genetic biomarkers in idiopathic pulmonary fibrosis: where are we now? Biomedicines. 2023. Available from: https://doi.org/10.3390/biomedicines11102796
Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, et al. Beyond Steroids: Immunosuppressants in steroid-refractory or resistant Immune-related adverse events. J Thorac Oncol. 2021.;16(10):1759-1764. Available from: https://doi.org/10.1016/j.jtho.2021.06.024